.Nature Medicine, Published online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint calls for introduction of patients along with MASLD as well as dimension of liver outcomes in cardio-- kidney-- metabolic trials, when data suggest mechanistically conceivable perks and professional safety-- as well as details considerations for test design as well as regulatory commendation.